Nine months after Johnson & Johnson stepped back from an Addex Therapeutics-partnered epilepsy drug in the wake of a phase 2 ...

a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety ...

a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety ...

announced today that positive results from the Company’s novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented ...

I am particularly excited by studies with arbaclofen, a GABA-B receptor agonist that also corrects aberrant protein synthesis in the animal model. Treatment of children with arbaclofen in placebo ...

Low GABA levels have been linked to generalized anxiety disorder (GAD), panic attacks, and chronic stress. This is why GABA-modulating medications, like benzodiazepines (e.g., Xanax, Valium), are ...

Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a ...

Finally, the SSRI-induced increase in serotonin concentration potentially impacts numerous serotonin receptor subtypes, spanning multiple signaling processes (pre- and post-synaptic, excitatory ...